{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:59:15Z","timestamp":1760014755738},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.diagmicrobio.2011.05.012","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T01:19:40Z","timestamp":1313543980000},"page":"93-97","source":"Crossref","is-referenced-by-count":21,"title":["Update on the telavancin activity tested against European staphylococcal clinical isolates (2009\u20132010)"],"prefix":"10.1016","volume":"71","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","author":"Clinical and Laboratory Standards Institute (CLSI)","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - 8th edition. M07-A8","key":"10.1016\/j.diagmicrobio.2011.05.012_bb0005"},{"year":"2011","author":"Clinical and Laboratory Standards Institute (CLSI)","article-title":"Performance standards for antimicrobial susceptibility testing","key":"10.1016\/j.diagmicrobio.2011.05.012_bb0010"},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0015","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/AAC.01641-07","article-title":"Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States","volume":"52","author":"Draghi","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/TCRM.S1843","article-title":"A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)","volume":"4","author":"Dunbar","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"year":"2011","author":"EUCAST","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, March 2011","key":"10.1016\/j.diagmicrobio.2011.05.012_bb0030"},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0035","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1378\/chest.09-2453","article-title":"Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia","volume":"138","author":"Haque","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0040","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0050","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant Gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0055","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01544-08","article-title":"Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"53","author":"Leonard","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0060","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0065","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JCM.02135-08","article-title":"Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years","volume":"47","author":"Musta","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.diagmicrobio.2010.03.009","article-title":"Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results","volume":"67","author":"Putnam","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0080","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0085","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0095","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin. Infect. Dis."},{"author":"VIBATIV Package Insert","key":"10.1016\/j.diagmicrobio.2011.05.012_bb0100"},{"key":"10.1016\/j.diagmicrobio.2011.05.012_bb0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"Yoon","year":"2010","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T12:56:55Z","timestamp":1543582615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889311002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0732889311002136"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2011.05.012","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}